Last reviewed · How we verify
NCT05005091: oralcarbohydra
Effect of Preoperative Oral Carbohydrate Administration in Thoracic Surgery Patients
NA trial testing Oral carbohydrate in Non Small Cell Lung Cancer in 94 participants. Completed in 30 April 2018.
30 April 2018
Quick facts
| Lead sponsor | Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 94 |
| Start date | 1 January 2017 |
| Primary completion | 30 April 2018 |
| Estimated completion | 30 April 2018 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Oral carbohydrate
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
- Fasting — all drugs for Fasting →
- Postoperative Pneumonia — all drugs for Postoperative Pneumonia →
Sponsor
Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital
Who can join
Adults 18 to 80, any sex, with Non Small Cell Lung Cancer or Fasting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Preoperative carbohydrate loading has been shown to reduce pre-operative discomfort and postoperative nausea and vomiting. There is no need for prolonged preoperative fasting of the patients, but the traditional approach still continues especially in thoracic surgery patients. For this purpose, we aimed to evaluate the effect of preoperative carbohydrate loading on postoperative morbidity in the patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05005091
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Other Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital trials
Trials by the same sponsor.
- NCT05894733 — The Effects of Frequent Follow up on Compliance in Patients Receiving PAP Therapy Due to OSA (Pap: Positive Airway Press · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05005091 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital
- Last refreshed: 13 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05005091.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing